Monthly Communication Report

Corporation:	AstraZeneca Canada Inc.
Associated registration:	957438-15042-64
Communication date:	2026-02-13
Posted date:	2026-03-27

Designated Public Office Holders who participated in the communication:	Simon Lacroix, Office Director House of Commons Linda Lapointe, Member of Parliament House of Commons
List of Details Subject matter Detail Economic Development, Health, International Trade, Research and Development, Taxation and Finance Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Economic Development, Federal-Provincial Relations, Health, Industry, Intellectual Property, Research and Development Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Responsible Officer who filed this communication report:	Gaby Bourbara
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.